Patents by Inventor Christine Strick

Christine Strick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050026236
    Abstract: The invention features a method of screening for an agent that inhibits intracellular phosphodiesterase 10A activity, comprising administering an agent to striatal medium spiny neurons and submaximally activating adenylate cyclase, administering an agent to striatal medium spiny neurons and submaximally activating guanylate cyclase, measuring cAMP generation and cGMP generation in the cells, and calculating the cAMP EC200 and the cGMP EC200, wherein the agent is identified as a PDE10A inhibitor if the ratio of cAMP EC200/cGMP EC200 is comparable to the ratio produced by administration of papaverine under the same assay conditions. Also featured are rat PDE10A polynucleotide and polypeptide sequences.
    Type: Application
    Filed: July 8, 2004
    Publication date: February 3, 2005
    Inventors: Larry James, Lorraine Lebel, Frank Menniti, Christine Strick
  • Publication number: 20030121069
    Abstract: The invention features non-human mammals and animal cells that contain a targeted disruption of a phosphodiesterase 10A (PDE10A) gene.
    Type: Application
    Filed: December 19, 2002
    Publication date: June 26, 2003
    Applicant: Pfizer Inc.
    Inventors: Frank S. Menniti, Christopher J. Schmidt, Jeffrey L. Stock, Christine A. Strick
  • Publication number: 20030096323
    Abstract: The invention features a method of screening for an agent that inhibits intracellular phosphodiesterase 10A activity, comprising administering an agent to striatal medium spiny neurons and submaximally activating adenylate cyclase, administering an agent to striatal medium spiny neurons and submaximally activating guanylate cyclase, measuring cAMP generation and cGMP generation in the cells, and calculating the cAMP EC200 and the cGMP EC200, wherein the agent is identified as a PDE10A inhibitor if the ratio of cAMP EC200/cGMP EC200 is comparable to the ratio produced by administration of papaverine under the same assay conditions. Also featured are rat PDE10A polynucleotide and polypeptide sequences.
    Type: Application
    Filed: July 24, 2002
    Publication date: May 22, 2003
    Applicant: Pfizer Inc.
    Inventors: Larry C. James, Lorraine A. Lebel, Frank S. Menniti, Christine A. Strick
  • Patent number: 5786212
    Abstract: This invention relates to modified Yarrowia lipolytica LEU2 gene promoters; modified Y. lipolytica LEU2 genes comprising such modified Y. lipolytica LEU2 gene promoters; and vectors comprising such modified Y. lipolytica LEU2 genes. This invention also relates to vectors comprising a Y. lipolytica DNA sequence LEU2 genes. This invention also relates to vectors comprising a Y. lipolytica DNA sequence sufficient for integrative transformation of Y. lipolytica; vectors which comprise a nucleotide sequence coding for a polypeptide and a promoter functional in Y. lipolytica operably linked thereto; E. coli transformants which comprise vectors according to this invention; Y. lipolytica transormants which comprise an expression vector according to this invention; methods of producing Y. lipolytica transformants comprising multiple integrated expression vectors; strains of Y. lipolytica useful in the preparation of such transformants; methods of producing polypeptides with certain of the Y.
    Type: Grant
    Filed: May 6, 1996
    Date of Patent: July 28, 1998
    Assignee: Pfizer Inc.
    Inventors: Larry C. James, Christine A. Strick